Fred McMahon

Fred McMahon is a seasoned executive in the biopharmaceutical industry, currently serving as Chief Business Officer at Crosswalk Therapeutics since December 2023. Previously, McMahon was Senior Vice President of Business Development at CENTOGENE, where a partnering team focused on genetic and neurodegenerative disease drug development was established. Earlier roles include Vice President positions at Takeda, leading product strategy in rare genetics and hematology, and Shire, where McMahon oversaw global product strategy for rare diseases. Experience also encompasses key positions at Biogen Idec, L.E.K. Consulting, Mundipharma, and Singapore Health Services, along with an early career in M&A advisory services. McMahon holds an MBA in Healthcare Management from The Wharton School and a BA in Politics from Princeton University.